MLabs now offers new approved therapy with KEYTRUDA through the PD-L1 (22C3 Assay). KEYTRUDA is a medicine that may treat certain cancers by working with your immune system. This FDA approved companion diagnostic for KEYTRUDA to evaluate triple-negative breast cancer patients.
The detection of DDIT3 rearrangements can be useful in diagnosing myxoid liposarcoma – including uncommon histologic variants – and in distinguishing this sarcoma from other mesenchymal tumors that may be considered in the differential diagnosis.
In an effort to ensure the safety of our faculty and staff, while maintaining service excellence for our clients and mutual patients, Michigan Medicine Laboratories (MLabs) has updated our tissue submission requirements.
We have changed our location for COVID testing to an inside drive through to Huron Valley Ambulance Center (HVA).
MLabs is now offering PDL-1 testing for Metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1.
NOW AVAILABLE: NGS Myeloid Panel! MLabs is excited to announce the addition of our new NGS Myeloid
Panel: For any myeloid or suspected myeloid neoplasm.
Serology testing for SARS-CoV-2 is now available for ordering. A separate process for testing and screening of health care workers and Michigan Medicine affiliates will be communicated in the coming weeks.
Many patients living with metastatic breast cancer (mBS) now have a new treatment option.
In May 2019, the FDA approved a new targeted therapy, alpelisib (Piqray®). An oral medication intended to be used in combination with fulvestrant (Faslodex®), Piqray® is...
MLabs next-generation sequencing (NGS) offerings include Solid Tumor, Lung Cancer, Colorectal Cancer, and Melanoma NGS Panels. These NGS tests target 50 genes to detect substitution and insertion/deletion mutations (35 genes), gene amplifications (19 genes), and gene fusions (21 genes) including NTRK gene fusions...